Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective StudyConference abstracts
ConclusionsOccult nodal disease was frequently identified in peripheral N1 stations (11-13) in patients with small (≤2 cm) clinical N0 NSCLC. Hilar lymphadenectomy is essential for accurate staging in the management of patients with small clinical N0 NSCLC.
Publication date: April 2020Source: Food Control, Volume 110Author(s): Rodrigo C. Oliveira, Magda Carvajal-Moreno, Pedro Mercado-Ruaro, Francisco Rojo-Callejas, Benedito CorreaAbstractIn the present study, we offer detailed insights into the mechanisms of action of clove and rosemary essential oils (EOs) on Aspergillus flavus and provide evidence that the induction of apoptosis-like cell death and the downregulation of metabolic genes trigger their antifungal and anti-aflatoxigenic effects. The mode of action of both EOs at the cellular level was investigated through the detection of early (nuclear condensation) and late a...
According to this study, a more accurate encapsulation condition into lysosome can be optimized and potential application of S. cerevisiae derived lysosomes as drug carriers is confirmed.
Epigenomics, Ahead of Print.
Thiopurines, including mercaptopurine, are a cornerstone of modern maintenance therapy for childhood acute lymphoblastic leukemia (ALL) and various other diseases. Thiopurine methyltransferase (TPMT) is a pivotal enzyme in the degradation of toxic thiopurine metabolites. Individuals heterozygous for inactivating TPMT variants (about 10% of the European and American population) require modest decreases in thiopurine dosing, whereas those with homozygous defects tolerate only about one-tenth the conventional dose.
Conclusions. ISV is widely used in hematological pts with IFI also in diseases other than acute myeloid leukemia and it is overall well tolerated. ORR to ISV is at least comparable with other antifungal agents. A rec/ref underlying hematological disease impacts both on OS and response to ISV, while having an IFI refractory to other antifungal agents including azoles does not seem to compromise the response to ISV, although this promising result should be confirmed in prospective studies and larger groups of patients.DisclosuresBusca: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Sp...
Summary Posaconazole was introduced as the primary antifungal prophylaxis (PAP) in acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) patients during remission induction chemotherapy. Data on breakthrough invasive fungal infections (IFIs) from various centres are essential, as there are several considerations in treating IFIs in the posaconazole era. The aim of this study was to evaluate the effectiveness of posaconazole PAP and identify characteristics of IFIs at a single centre in Korea. We retrospectively reviewed consecutive patients with AML/MDS undergoing remission induction chemotherapy between December...
Conclusions. A combined monitoring strategy based on serum GM and Aspergillus DNA was associated with an earlier diagnosis and a lower incidence of IA in high-risk hematological patients. Clinical Trials Registration. NCT01742026.